Your browser doesn't support javascript.
loading
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
Grande, E; Capdevila, J; Castellano, D; Teulé, A; Durán, I; Fuster, J; Sevilla, I; Escudero, P; Sastre, J; García-Donas, J; Casanovas, O; Earl, J; Ortega, L; Apellaniz-Ruiz, M; Rodriguez-Antona, C; Alonso-Gordoa, T; Díez, J J; Carrato, A; García-Carbonero, R.
Afiliação
  • Grande E; Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid. Electronic address: egrande@oncologiahrc.com.
  • Capdevila J; Department of Medical Oncology, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona.
  • Castellano D; Department of Medical Oncology, I + 12 Research Institute, 12 de Octubre University Hospital, Madrid.
  • Teulé A; Department of Medical Oncology, IDIBELL, Catalan Institute of Oncology L'Hospitalet, Barcelona.
  • Durán I; Department of Medical Oncology, Instituto de Biomedicina de Sevilla (IBIS) [HUVR, CSIC, University of Seville], Virgen del Rocío University Hospital, Seville.
  • Fuster J; Department of Medical Oncology, Son Espases Hospital, Palma de Mallorca.
  • Sevilla I; Department of Medical Oncology, Virgen de la Victoria University Hospital, Malaga.
  • Escudero P; Department of Medical Oncology, Clínico Lozano Blesa University Hospital, Zaragoza.
  • Sastre J; Department of Medical Oncology, Clínico San Carlos Hospital, Madrid.
  • García-Donas J; Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Madrid.
  • Casanovas O; Tumor Angiogenesis Group, IDIBELL, Catalan Institute of Oncology L'Hospitalet, Barcelona.
  • Earl J; Department of Medical Oncology Research Laboratory, Ramón y Cajal University Hospital, Madrid.
  • Ortega L; Department of Pathology, Clínico San Carlos Hospital, Madrid.
  • Apellaniz-Ruiz M; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center, ISCIII Center for Biomedical Research on Rare Disease (CIBERER) Madrid, Madrid.
  • Rodriguez-Antona C; Hereditary Endocrine Cancer Group, Spanish National Cancer Research Center, ISCIII Center for Biomedical Research on Rare Disease (CIBERER) Madrid, Madrid.
  • Alonso-Gordoa T; Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid.
  • Díez JJ; Department of Endocrinology, Ramón y Cajal University Hospital, Madrid, Spain.
  • Carrato A; Department of Medical Oncology, Ramón y Cajal University Hospital, Madrid.
  • García-Carbonero R; Department of Medical Oncology, Instituto de Biomedicina de Sevilla (IBIS) [HUVR, CSIC, University of Seville], Virgen del Rocío University Hospital, Seville.
Ann Oncol ; 26(9): 1987-1993, 2015 Sep.
Article em En | MEDLINE | ID: mdl-26063633
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Pirimidinas / Sulfonamidas / Biomarcadores Tumorais / Tumores Neuroendócrinos / Inibidores da Angiogênese Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Pirimidinas / Sulfonamidas / Biomarcadores Tumorais / Tumores Neuroendócrinos / Inibidores da Angiogênese Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2015 Tipo de documento: Article